Ratings Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Real-time Estimate Cboe BZX Other stock markets 02:14:41 2024-04-26 pm EDT			5-day change	1st Jan Change
11.24 ^USD	+0.58%		-4.70%	-19.56%

Apr. 01	Dynavax Technologies Corporation Announces Chief Financial Officer Changes	CI
Feb. 23	Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 48.57 and 31.03 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
DYNAVAX TECHNOLOGIES CORPORATION	-19.56%	1.46B	B-
VERTEX PHARMACEUTICALS INCORPORATED	-2.03%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.67%	95.71B	B+
ARGENX SE	+1.69%	22.02B	B
BIONTECH SE	-17.06%	20.9B	B+
GENMAB A/S	-9.30%	17.85B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.21B	A-
BEIGENE, LTD.	-14.87%	15.52B	B
NEUROCRINE BIOSCIENCES, INC.	+3.34%	13.86B	C+
SAREPTA THERAPEUTICS, INC.	+35.13%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes